minocycline and Attention-Deficit-Disorder-with-Hyperactivity

minocycline has been researched along with Attention-Deficit-Disorder-with-Hyperactivity* in 1 studies

Other Studies

1 other study(ies) available for minocycline and Attention-Deficit-Disorder-with-Hyperactivity

ArticleYear
Minocycline fails to treat chronic traumatic brain injury-induced impulsivity and attention deficits.
    Experimental neurology, 2022, Volume: 348

    Traumatic brain injury (TBI) impacts millions worldwide and can cause lasting psychiatric symptoms. Chronic neuroinflammation is a characteristic of post-injury pathology and is also associated with psychiatric conditions such as ADHD and bipolar disorder. Therefore, the current study sought to determine whether TBI-induced impulsivity and inattention could be treated using minocycline, an antibiotic with anti-inflammatory properties. Rats were trained on the five-choice serial reaction time task (5CSRT), a measure of motor impulsivity and attention. After behavior was stable on the 5CSRT, rats received either a bilateral frontal TBI or sham procedure. Minocycline was given at either an early (1 h post-injury) or chronic (9 weeks post-injury) timepoint. Minocycline was delivered every 12 h for 5 days (45 mg/kg, i.p.). Behavioral testing on the 5CSRT began again after one week of recovery and continued for 12 more weeks, then rats were transcardially perfused. Impulsivity and inattention were both substantially increased following TBI. Minocycline had no therapeutic effects at either the early or late time points. TBI rats had increased lesion volume, but minocycline did not attenuate lesion size. Additionally, microglia count measured by IBA-1

    Topics: Animals; Anti-Bacterial Agents; Attention Deficit Disorder with Hyperactivity; Brain Injuries, Traumatic; Impulsive Behavior; Inflammation Mediators; Male; Minocycline; Rats; Rats, Long-Evans; Reaction Time; Treatment Failure

2022